2021
Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae
Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, Marx FM, Meghji J, Pedrazzoli D, Salomon JA, Sweeney S, van Kampen SC, Wallis RS, Houben RMGJ, Cohen T. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. The Lancet Global Health 2021, 9: e1679-e1687. PMID: 34798027, PMCID: PMC8609280, DOI: 10.1016/s2214-109x(21)00367-3.Peer-Reviewed Original ResearchConceptsPost-tuberculosis sequelaeBurden estimatesTuberculosis diseaseDisease episodesIncident tuberculosisIncident tuberculosis casesIncident tuberculosis diseaseNon-fatal health lossOverall disease burdenPulmonary tuberculosis diseaseLifetime health outcomesDisease burden estimatesElevated mortality riskHigh incidence rateExtrapulmonary diseaseLung functionCase fatalityHIV statusLifetime burdenTuberculosis casesTotal DALYsDisease burdenIncidence rateHypothetical cohortTuberculosis survivors
2016
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis
Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLOS Medicine 2016, 13: e1002142. PMID: 27727274, PMCID: PMC5058480, DOI: 10.1371/journal.pmed.1002142.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisMDR-TB treatmentTB treatmentSecondary casesDrug-resistant (XDR) TBResistance patternsLife expectancyMultidrug-resistant TB patientsDrug bedaquilineMDR-TB drugsAnti-tuberculosis drug bedaquilineCulture conversionMDR patientsTB patientsMortality benefitBedaquiline resistanceMedian timeRisk of resistanceTB drugsDecrease transmissionHypothetical cohortSources of heterogeneityDrug interactionsInitial cohortTime of initiation